iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
118 hedge funds and large institutions have $1.55B invested in iTeos Therapeutics in 2021 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 37 increasing their positions, 24 reducing their positions, and 4 closing their positions.
1,050% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 4
85% more capital invested
Capital invested by funds: $841M → $1.55B (+$712M)
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
54% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 24
53% more funds holding
Funds holding: 77 → 118 (+41)
6.23% more ownership
Funds ownership: 88.47% → 94.71% (+6.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$14.7M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.73M |
| 5 |
Millennium Management
New York
|
+$7.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$15M |
| 2 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$13.5M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$8.73M |
| 4 |
Citigroup
New York
|
-$6.82M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.45M |
ITOS Hedge Fund Activity: Q4 2021 in Review
118 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2021, worth a combined $1.55B — up 85% from $841M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new ITOS positions and 4 closed out — a net gain of 42 holders — while 37 added to existing stakes and 24 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $15M. The largest seller was Artal Group, cutting an estimated $15M.
- 118 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2021, up from 77 in Q3 2021.
- Funds reported $1.55B of iTeos Therapeutics stock for Q4 2021, up 85% quarter-over-quarter.
- 46 funds opened new iTeos Therapeutics positions in Q4 2021 and 4 closed out, a net change of +42 holders.
- The largest iTeos Therapeutics buyer in Q4 2021 was Octagon Capital Advisors, an estimated $15M added.
- The largest iTeos Therapeutics seller in Q4 2021 was Artal Group, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2021.